Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AptarGroupATR +2.71%78 EV-to-EBIT is 17.51 as of Jul. 15, 2026, which is 24% below its 10-year median of 22.96. GuruFocus rates ATR with a GF Score™ of 78/100 and a GF Value™ of $157.49 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 466 Medical Devices & Instruments companies, AptarGroup ranks better than 55.58% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AptarGroup's Enterprise Value for the quarter that ended in Mar. 2026 was $9,278 Mil.
AptarGroup's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $537 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AptarGroup EV-to-EBIT Related Terms
AptarGroup EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AptarGroup's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AptarGroup's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AptarGroup EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AptarGroup's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AptarGroup's EV-to-EBIT falls into.
AptarGroup's current Enterprise Value is $9,412 Mil.
AptarGroup's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $537 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AptarGroup (ATR) has a EV-to-EBIT of 17.51 as of Jul. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AptarGroup and its competitors. This is 24% below median its historical median of 22.96. Over the past decade, AptarGroup's EV-to-EBIT has ranged from 15.55 to 33.64. According to the industry distribution chart, AptarGroup ranks #207 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 44.4%.
Is AptarGroup's EV-to-EBIT too high?
AptarGroup's current EV-to-EBIT of 17.51 is 24% below median its 10-year median of 22.96. Over the past 10 years, this metric has ranged from a low of 15.55 to a high of 33.64. The Medical Devices & Instruments industry median EV-to-EBIT is 18.74. AptarGroup's value of 17.51 is 6.6% below this industry median. Based on the distribution chart, AptarGroup ranks #207 out of 466 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AptarGroup has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AptarGroup's EV-to-EBIT compare to RGEN and AVTR?
According to the Medical Devices & Instruments industry distribution chart, AptarGroup ranks #207 out of 466 companies for EV-to-EBIT. This puts AptarGroup in the upper half of its industry. The industry median EV-to-EBIT is 18.74. AptarGroup's value of 17.51 is 6.6% below this benchmark. Historically, AptarGroup's own EV-to-EBIT has ranged from 15.55 to 33.64 over the past decade. While the company's 10-year median is 22.96 vs. the industry median of 18.74, AptarGroup has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.74, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AptarGroup's current EV-to-EBIT of 17.51 is 6.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AptarGroup and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AptarGroup's current EV-to-EBIT is 17.51, which is 24% below median its own 10-year median of 22.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AptarGroup stock overvalued right now?
Based on GuruFocus' analysis, AptarGroup (ATR) is currently considered Modestly Undervalued. The stock's GF Value™ is $157.49, compared to a current price of $128.28 — trading 18.5% below its estimated fair value. The current EV-to-EBIT is 17.51, which is 24% below median its 10-year median of 22.96 and 6.6% below the Medical Devices & Instruments industry median of 18.74. AptarGroup's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AptarGroup (ATR), the current EV-to-EBIT is 17.51 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AptarGroup (ATR) Overvalued in 2026?
Based on GuruFocus' analysis, AptarGroup stock appears to be undervalued.
The current stock price of $128.28 is trading 18.5% below its estimated GF Value™ of $157.49.
GuruFocus considers AptarGroup to be Modestly Undervalued.
Key valuation signals for ATR:
EV-to-EBIT: 17.51 (24% below median its 10-year median of 22.96)
GF Value™: $157.49 vs. price of $128.28 (18.5% below fair value)
Industry Position: 6.6% below the Medical Devices & Instruments median (#207 of 466)
No single metric tells the full story. See the ATR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
78GF Score
Get the complete analysis for ATR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATR has been successfully added to your 
